Using emodin to treat heart damage caused by alcohol
Official title: Developing natural compound emodin as a therapy for alcoholic cardiomyopathy
Funded at Acepre, LLC · NIH-10808869 · Data updated 2026-11-12
This study is looking at how a natural compound called emodin might help protect the heart from damage caused by heavy drinking, and it's aimed at finding a new treatment for people with alcoholic cardiomyopathy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Acepre, LLC NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | March 15, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $461,518 |
| NIH project number | 5UT1AA030690-02 |
| Project ID | NIH-10808869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with alcoholic cardiomyopathy or those experiencing heart issues related to chronic alcohol use.
✕Less likely to help
Patients who do not consume alcohol or have heart conditions unrelated to alcohol use may not benefit from this research.
What this research studies
This research focuses on alcoholic cardiomyopathy (ACM), a serious heart condition caused by excessive alcohol consumption. The project aims to develop emodin, a natural compound known for its anti-inflammatory and protective properties, as a potential therapy for ACM. Researchers will investigate how emodin can prevent heart damage by targeting specific cellular mechanisms involved in the disease. The study will involve preclinical testing to assess the effectiveness and safety of emodin in treating heart issues related to alcohol use.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from heart damage due to alcohol consumption.
How similar studies have gone: Previous research has shown promise in using natural compounds like emodin for heart-related conditions, indicating potential for success in this approach.
Where this research is happening
-
Acepre, LLC
Columbia, United States Active
Researchers
- Principal investigator: Carver, Wayne E — Acepre, LLC
- Study coordinator: Carver, Wayne E
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.